@article{3084281, title = "Non-endothelial KDR/flk-1 expression is associated with increased survival of patients with urothelial bladder carcinomas", author = "Gakiopoulou-Givalou, H and Nakopoulou, L and Panayotopoulou, EG and and Zervas, A and Mavrommatis, J and Giannopoulos, A", journal = "Diagnostic Histopathology", year = "2003", volume = "43", number = "3", pages = "272-279", publisher = "Wiley-Blackwell Publishing Ltd", issn = "1756-2317", doi = "10.1046/j.1365-2559.2003.01690.x", keywords = "KDR/flk-1; urothelial bladder cancer; Ki67; Bcl-2; p53; survival; non-endothelial expression", abstract = "Aims: To investigate the immunohistochemical expression of KDR/flk-1 in a series of 114 urothelial bladder carcinomas in relation to clinicopathological parameters, Ki67, p53 and Bcl-2 protein expression and patient survival. KDR/flk-1 is a high-affinity tyrosine kinase receptor for vascular endothelial growth factor (VEGF), on vascular endothelium. However, there is increasing evidence that KDR/flk-1 is also expressed by normal non-endothelial and tumour cells. Methods and results: Immunohistochemistry was performed on paraffin sections using monoclonal and polyclonal antibodies. Statistical analysis was univariate (chi(2) log rank test) and multivariate (Cox’s model). KDR/flk-1 expression was observed in the cytoplasm of cancerous cells in 68.4% of cases. No statistically significant associations were observed between KDR/flk-1 expression and grade or stage of urothelial carcinomas, Ki67, p53 or Bcl-2 expression. In contrast, widespread KDR/flk-1 expression in more than 50% of cancerous cells was associated with increased survival, on univariate and multivariate analysis (P = 0.0119 and P = 0.042, respectively). Conclusions: Although the biological significance of non-endothelial KDR/flk-1 expression has not yet been elucidated, its association with better patient survival may be related to the failure of non-endothelial KDR/flk-1 to mediate angiogenic and mitogenic effects." }